DE69810603T2 - Gerät und verfahren für automatischen protein-entwurf - Google Patents

Gerät und verfahren für automatischen protein-entwurf

Info

Publication number
DE69810603T2
DE69810603T2 DE69810603T DE69810603T DE69810603T2 DE 69810603 T2 DE69810603 T2 DE 69810603T2 DE 69810603 T DE69810603 T DE 69810603T DE 69810603 T DE69810603 T DE 69810603T DE 69810603 T2 DE69810603 T2 DE 69810603T2
Authority
DE
Germany
Prior art keywords
protein design
automatic protein
automatic
design
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69810603T
Other languages
English (en)
Other versions
DE69810603D1 (de
Inventor
Stephen Mayo
I Dahiyat
Benjamin Gordon
Arthur Street
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
California Institute of Technology CalTech
Original Assignee
California Institute of Technology CalTech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Institute of Technology CalTech filed Critical California Institute of Technology CalTech
Application granted granted Critical
Publication of DE69810603D1 publication Critical patent/DE69810603D1/de
Publication of DE69810603T2 publication Critical patent/DE69810603T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1089—Design, preparation, screening or analysis of libraries using computer algorithms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/003—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by transforming the C-terminal amino acid to amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
DE69810603T 1997-04-11 1998-04-10 Gerät und verfahren für automatischen protein-entwurf Expired - Fee Related DE69810603T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4346497P 1997-04-11 1997-04-11
US5467897P 1997-08-04 1997-08-04
US6109797P 1997-10-03 1997-10-03
PCT/US1998/007254 WO1998047089A1 (en) 1997-04-11 1998-04-10 Apparatus and method for automated protein design

Publications (2)

Publication Number Publication Date
DE69810603D1 DE69810603D1 (de) 2003-02-13
DE69810603T2 true DE69810603T2 (de) 2003-11-13

Family

ID=27366337

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69810603T Expired - Fee Related DE69810603T2 (de) 1997-04-11 1998-04-10 Gerät und verfahren für automatischen protein-entwurf

Country Status (8)

Country Link
US (11) US6188965B1 (de)
EP (1) EP0974111B1 (de)
JP (1) JP2002510966A (de)
AU (1) AU751331B2 (de)
CA (1) CA2286262A1 (de)
DE (1) DE69810603T2 (de)
DK (1) DK0974111T3 (de)
WO (1) WO1998047089A1 (de)

Families Citing this family (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7047171B1 (en) * 1995-12-08 2006-05-16 Sproch Norman K Method for the characterization of the three-dimensional structure of proteins employing mass spectrometric analysis and computational feedback modeling
US20060277017A1 (en) * 1993-11-04 2006-12-07 Sproch Norman K Method for the characterization of the three-dimensional structure of proteins employing mass spectrometric analysis and computational feedback modeling
DE69810603T2 (de) * 1997-04-11 2003-11-13 California Inst Of Techn Gerät und verfahren für automatischen protein-entwurf
US7315786B2 (en) * 1998-10-16 2008-01-01 Xencor Protein design automation for protein libraries
US20020048772A1 (en) * 2000-02-10 2002-04-25 Dahiyat Bassil I. Protein design automation for protein libraries
US20030049654A1 (en) * 1998-10-16 2003-03-13 Xencor Protein design automation for protein libraries
US6403312B1 (en) 1998-10-16 2002-06-11 Xencor Protein design automatic for protein libraries
AU774334B2 (en) * 1998-10-16 2004-06-24 Xencor Protein design automation for protein libraries
US6627186B1 (en) 1999-01-06 2003-09-30 Xencor Nucleic acids and protein variants of hG-CSF with granulopoietic activity
US7208473B2 (en) 1999-01-06 2007-04-24 Xencor, Inc. Nucleic acids and protein variants of hG-CSF with granulopoietic activity
WO2000042559A1 (en) * 1999-01-18 2000-07-20 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6917882B2 (en) * 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
EP1130093A1 (de) 1999-01-19 2001-09-05 Maxygen, Inc. Oligonukleotiden-gesteuerte Nukleinsäurenrekombination
US7873477B1 (en) 2001-08-21 2011-01-18 Codexis Mayflower Holdings, Llc Method and system using systematically varied data libraries
US8457903B1 (en) 1999-01-19 2013-06-04 Codexis Mayflower Holdings, Llc Method and/or apparatus for determining codons
US20070065838A1 (en) * 1999-01-19 2007-03-22 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US7702464B1 (en) 2001-08-21 2010-04-20 Maxygen, Inc. Method and apparatus for codon determining
US7024312B1 (en) * 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
WO2000047612A2 (en) * 1999-02-11 2000-08-17 Xencor, Inc. Structure-based screening techniques for drug discovery
US6864359B1 (en) 1999-02-11 2005-03-08 Xencor Structure-based screening techniques for drug discovery
JP3892167B2 (ja) * 1999-03-19 2007-03-14 富士通株式会社 粒子集団の配置を生成する生成装置および方法
US6343257B1 (en) 1999-04-23 2002-01-29 Peptor Ltd. Identifying pharmacophore containing combinations of scaffold molecules and substituents from a virtual library
AU5132900A (en) * 1999-05-12 2000-11-21 Xencor, Inc. Novel nucleic acids and proteins with growth hormone activity
US6946265B1 (en) 1999-05-12 2005-09-20 Xencor, Inc. Nucleic acids and proteins with growth hormone activity
US6682923B1 (en) 1999-05-12 2004-01-27 Xencor Thermostable alkaliphilic xylanase
WO2000068396A2 (en) * 1999-05-12 2000-11-16 Xencor, Inc. Bacillus circulans xylanase mutants
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US6334099B1 (en) * 1999-05-25 2001-12-25 Digital Gene Technologies, Inc. Methods for normalization of experimental data
WO2001039098A2 (en) * 1999-11-22 2001-05-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem System and method for searching a combinatorial space
WO2001016862A2 (en) * 1999-09-01 2001-03-08 California Institute Of Technology Methods and compositions utilizing a branch and terminate algorithm for protein design
US7430477B2 (en) * 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
EP1226528B1 (de) 1999-11-03 2006-10-04 Algonomics N.V. Verfahren zum generieren von informationen in zusammenhang mit der molekularstruktur eines biomoleküls
EP1242925A2 (de) 1999-11-03 2002-09-25 Algonomics N.V. Apparat und verfahren für strukturbasierte vorhersage von aminosäuresequenzen
JP3964087B2 (ja) * 1999-12-24 2007-08-22 株式会社カネカ 多重変異蛋白質アミノ酸配列の最適化解を算出する方法、装置、およびこの方法の処理を実行するプログラムを記憶する記憶媒体
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
EP1621617A1 (de) * 2000-02-10 2006-02-01 Xencor, Inc. Automatisierte Proteinkonstruktion für Proteinbibliotheken
DE60113381T2 (de) * 2000-02-10 2006-06-29 Xencor, Monrovia Automatisierung im proteinentwurf durch proteinbibliotheken
US7244823B2 (en) 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US7662367B2 (en) 2000-03-02 2010-02-16 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-α related disorders
US20070172449A1 (en) * 2000-03-02 2007-07-26 Xencor, Inc. TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
CA2401683A1 (en) * 2000-03-02 2001-09-07 Xencor Design and discovery of protein based tnf-.alpha. variants for the treatment of tnf-.alpha. related disorders
US7446174B2 (en) 2001-03-02 2008-11-04 Xencor, Inc. Protein based TNF-α variants for the treatment of TNF-α related disorders
US7056695B2 (en) 2000-03-02 2006-06-06 Xencor TNF-α variants
US7101974B2 (en) * 2000-03-02 2006-09-05 Xencor TNF-αvariants
US7687461B2 (en) * 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US6983233B1 (en) 2000-04-19 2006-01-03 Symyx Technologies, Inc. Combinatorial parameter space experiment design
US20020052004A1 (en) * 2000-05-24 2002-05-02 Niles Pierce Methods and compositions utilizing hybrid exact rotamer optimization algorithms for protein design
US6586207B2 (en) * 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
DE10028875A1 (de) * 2000-06-10 2001-12-20 Hte Gmbh Rechnergestützte Optimierung von Substanzbibliotheken
AU2001282880A1 (en) 2000-07-07 2002-01-21 California Institute Of Technology Proteins with integrin-like activity
EP1330766A2 (de) * 2000-07-10 2003-07-30 Xencor Verfahren zum entwerfen von proteinbibliotheken mit modifizierter immunogenität
IL137886A0 (en) 2000-08-16 2001-10-31 Univ Ramot A novel algorithm for de novo protein design
AU2001280077A1 (en) * 2000-08-16 2002-02-25 Ramot University Authority For Applied Research And Industrial Development Ltd. Method and system for predicting amino acid sequence
AU2002230784A1 (en) * 2000-11-10 2002-05-21 Xencor Novel thermostable alkaliphilic xylanase
CA2431066C (en) * 2000-12-15 2007-05-15 Youqi Wang Methods and apparatus for designing high-dimensional combinatorial experiments
US7231328B2 (en) * 2001-02-06 2007-06-12 The Penn State Research Foundation Apparatus and method for designing proteins and protein libraries
US20030036854A1 (en) * 2001-02-06 2003-02-20 The Penn State Research Foundation Apparatus and method for designing proteins and protein libraries
US20020183937A1 (en) * 2001-02-09 2002-12-05 Stephen Mayo Method for the generation of proteins with new enzymatic function
WO2002073193A1 (en) * 2001-03-12 2002-09-19 Board Of Regents, The University Of Texas System Computer-based strategy for peptide and protein conformational ensemble enumeration and ligand affinity analysis
US20030032065A1 (en) * 2001-03-12 2003-02-13 Vince Hilser Ensemble-based strategy for the design of protein pharmaceuticals
EP1507852A4 (de) * 2001-05-04 2005-12-28 Xencor Inc Nukleinsäuren und proteine mit thioredoxinreduktasewirkung
US20030211511A1 (en) * 2001-05-04 2003-11-13 Briggs Steven P. Nucleic acids and proteins with thioredoxin reductase activity
US20030049680A1 (en) * 2001-05-24 2003-03-13 Gordon D. Benjamin Methods and compositions utilizing hybrid exact rotamer optimization algorithms for protein design
US7110525B1 (en) 2001-06-25 2006-09-19 Toby Heller Agent training sensitive call routing system
US20030022285A1 (en) * 2001-07-10 2003-01-30 Chirino Arthur J. Protein design automation for designing protein libraries with altered immunogenicity
EP1510959A3 (de) * 2001-08-10 2006-07-26 Xencor, Inc. Automatisierte Proteinkonstruktion für Proteinbibliotheken
US20030130827A1 (en) * 2001-08-10 2003-07-10 Joerg Bentzien Protein design automation for protein libraries
JP2005512168A (ja) * 2001-08-31 2005-04-28 オプティマム・パワー・テクノロジー・エルピー 設計最適化
US6822073B2 (en) * 2001-12-20 2004-11-23 Kimberly-Clark Worldwide, Inc. Modular peptide-based reagent
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
EP1490677A4 (de) * 2002-02-27 2006-01-18 California Inst Of Techn Computerberechnungsverfahren zur konstruktion von enzymen zum einbau von aminosäureanalogen in proteine
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20080254027A1 (en) * 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20030216867A1 (en) * 2002-03-26 2003-11-20 Campbell Phil G. Methods and systems for molecular modeling
CN1628316A (zh) * 2002-03-26 2005-06-15 科学与工业研究委员会 构建三维分子结构最佳模型的方法与系统
US20030215877A1 (en) * 2002-04-04 2003-11-20 California Institute Of Technology Directed protein docking algorithm
US7272545B2 (en) * 2002-05-22 2007-09-18 General Electric Company Method and apparatus for designing and locating chemical structures
CA2487006A1 (en) * 2002-05-23 2003-12-04 Vince Hilser Predicting the significance of single nucleotide polymorphisms (snps) using ensemble-based structural energetics
JP2005531850A (ja) * 2002-07-01 2005-10-20 ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド 自己組織化による配座サンプリング
DE10233047A1 (de) * 2002-07-19 2004-02-26 Amaxa Gmbh Verfahren zur Herstellung eines künstlichen Polypeptids und nach diesem Verfahren hergestelltes künstliches Protein
US20040082783A1 (en) * 2002-08-06 2004-04-29 Schafmeister Christian E. Bis (amino acid) molecular scaffolds
DK2345671T3 (en) 2002-09-27 2016-02-15 Xencor Inc Optimized Fc variants and methods for their formation
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
US20060014248A1 (en) * 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US20050221443A1 (en) * 2003-01-06 2005-10-06 Xencor, Inc. Tumor necrosis factor super family agonists
US20050130892A1 (en) * 2003-03-07 2005-06-16 Xencor, Inc. BAFF variants and methods thereof
US7553930B2 (en) * 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
CA2512693A1 (en) * 2003-01-08 2004-07-29 Xencor, Inc. Novel proteins with altered immunogenicity
DE602004025669D1 (de) * 2003-01-20 2010-04-08 Cambridge Entpr Ltd Rechnerisches verfahren und vorrichtung zur vorhersage der polypeptidaggregation oder lösbarkeit
US20040215400A1 (en) * 2003-01-21 2004-10-28 The Trustees Of The University Of Pennsylvania Computational design of a water-soluble analog of a protein, such as phospholamban and potassium channel KcsA
US9818136B1 (en) 2003-02-05 2017-11-14 Steven M. Hoffberg System and method for determining contingent relevance
US20040176585A1 (en) * 2003-02-27 2004-09-09 Carter Richard J. Method and system for determining optimal sequences
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20070275460A1 (en) * 2003-03-03 2007-11-29 Xencor.Inc. Fc Variants With Optimized Fc Receptor Binding Properties
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
EP1610825A2 (de) * 2003-03-31 2006-01-04 Xencor, Inc. Verfahren zur rationellen pegylierung von proteinen
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
WO2005007806A2 (en) * 2003-05-07 2005-01-27 Duke University Protein design for receptor-ligand recognition and binding
WO2005014641A2 (en) * 2003-07-09 2005-02-17 Xencor, Inc. Ciliary neurotrophic factor variants
WO2005052839A2 (en) * 2003-07-29 2005-06-09 California Institute Of Technology Systems and methods for predicting transmembrane domains in membrane proteins and mining the genome for recognizing g-protein coupled receptors
WO2005017805A2 (en) * 2003-08-13 2005-02-24 California Institute Of Technology Systems and methods for predicting the structure and function of multipass transmembrane proteins
US20050065879A1 (en) * 2003-09-18 2005-03-24 Convergys Information Management Group, Inc. System and method for web service billing
US7765175B2 (en) * 2003-09-18 2010-07-27 Optimum Power Technology, L.P. Optimization expert system
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
AU2004279895A1 (en) 2003-10-10 2005-04-21 Xencor, Inc Protein based TNF-alpha variants for the treatment of TNF-alpha related disorders
US6970790B2 (en) * 2003-10-14 2005-11-29 Verseon, Llc Method and apparatus for analysis of molecular combination based on computational estimation of electrostatic affinity using basis expansions
US20070149496A1 (en) * 2003-10-31 2007-06-28 Jack Tuszynski Water-soluble compound
WO2005044087A2 (en) * 2003-11-05 2005-05-19 The Regents Of The University Of California Methods for the determination of protein three-dimensional structure employing hydrogen exchange analysis to refine computational structure prediction
GB0325817D0 (en) * 2003-11-05 2003-12-10 Univ Cambridge Tech Method and apparatus for assessing polypeptide aggregation
WO2005047520A2 (en) * 2003-11-07 2005-05-26 Dna Software, Inc. System and methods for three dimensional molecular structural analysis
US7574306B1 (en) * 2003-11-20 2009-08-11 University Of Washington Method and system for optimization of polymer sequences to produce polymers with stable, 3-dimensional conformations
CA2548817A1 (en) * 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
US20060122783A1 (en) * 2004-08-24 2006-06-08 Ishikawa Muriel Y System and method for heightening a humoral immune response
US20070249809A1 (en) * 2003-12-08 2007-10-25 Xencor, Inc. Protein engineering with analogous contact environments
US20060003412A1 (en) * 2003-12-08 2006-01-05 Xencor, Inc. Protein engineering with analogous contact environments
EP1697520A2 (de) * 2003-12-22 2006-09-06 Xencor, Inc. Fc-polypeptide mit neuen fc-ligandenbindungsstellen
EP1737890A2 (de) * 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulinvarianten ausserhalb der fc-region
US20050260711A1 (en) * 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
US7603239B2 (en) * 2004-05-05 2009-10-13 Massachusetts Institute Of Technology Methods and systems for generating peptides
US20050287639A1 (en) * 2004-05-17 2005-12-29 California Institute Of Technology Methods of incorporating amino acid analogs into proteins
JP2008507591A (ja) * 2004-05-21 2008-03-13 ゼンコー・インコーポレイテッド 免疫原性が改変されたＣ１ｑファミリーメンバータンパク質
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US20060074225A1 (en) * 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
US20060136139A1 (en) * 2004-10-12 2006-06-22 Elcock Adrian H Rapid computational identification of targets
EP1827657B1 (de) * 2004-10-28 2015-04-22 Cerno Bioscience LLC Qualitative und quantitative massenspektralanalyse
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
KR101027427B1 (ko) 2004-11-12 2011-04-11 젠코어 인코포레이티드 ＦcRn에 대하여 증가된 결합력을 갖는 Ｆc 변이체
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
WO2006076594A2 (en) * 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
WO2006094234A1 (en) * 2005-03-03 2006-09-08 Xencor, Inc. Methods for the design of libraries of protein variants
US20080207467A1 (en) * 2005-03-03 2008-08-28 Xencor, Inc. Methods for the design of libraries of protein variants
US8742205B2 (en) 2005-07-29 2014-06-03 Targeted Growth, Inc. Dominant negative mutant KRP protein protection of active cyclin-CDK complex inhibition by wild-type KRP
US20070212700A1 (en) * 2005-09-07 2007-09-13 The Board Of Regents Of The University Of Texas System Methods of using and analyzing biological sequence data
US20070072226A1 (en) * 2005-09-27 2007-03-29 Indiana University Research & Technology Corporation Mining protein interaction networks
WO2007041635A2 (en) * 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
JP4860703B2 (ja) 2005-10-06 2012-01-25 ゼンコー・インコーポレイテッド 最適化された抗ｃｄ３０抗体
CN101300489A (zh) * 2005-11-03 2008-11-05 红点生物公司 Trpm5离子通道的高通量筛选实验
WO2007061850A2 (en) * 2005-11-17 2007-05-31 Massachusetts Institute Of Technology Methods and systems for generating and evaluating peptides
PT1999259E (pt) 2006-03-03 2014-09-24 California Inst Of Techn Incorporação sítio-específica de aminoácidos em moléculas
US20070208411A1 (en) * 2006-03-06 2007-09-06 Boston Scientific Scimed, Inc. Bifurcated stent with surface area gradient
US20070254307A1 (en) * 2006-04-28 2007-11-01 Verseon Method for Estimation of Location of Active Sites of Biopolymers Based on Virtual Library Screening
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
JP5313129B2 (ja) 2006-05-02 2013-10-09 アロザイン， インコーポレイテッド 非天然アミノ酸置換ポリペプチド
WO2007139037A1 (ja) * 2006-05-26 2007-12-06 Kyoto University ケミカルゲノム情報に基づく、タンパク質－化合物相互作用の予測と化合物ライブラリーの合理的設計
WO2008013861A2 (en) * 2006-07-27 2008-01-31 Redpoint Bio Corporation Screening assay for inhibitors of trpa1 activation by a lower alkyl phenol
PT2059536E (pt) 2006-08-14 2014-04-14 Xencor Inc Anticorpos otimizados que visam cd19
WO2008036688A2 (en) * 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
CN103965347B (zh) 2007-05-02 2017-07-18 Ambrx公司 经修饰干扰素β多肽和其用途
US7580304B2 (en) * 2007-06-15 2009-08-25 United Memories, Inc. Multiple bus charge sharing
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
WO2009045377A2 (en) * 2007-10-01 2009-04-09 Redpoint Bio Corporation A non-desensitizing mutant of the transient receptor potential trpm5 ion channel
AU2008326324B9 (en) 2007-11-20 2012-11-15 Ambrx, Inc. Modified insulin polypeptides and their uses
SI2235059T1 (sl) 2007-12-26 2015-06-30 Xencor, Inc. Fc variante s spremenjeno vezjo na fcrn
WO2009149218A2 (en) * 2008-06-03 2009-12-10 Codon Devices, Inc. Novel proteins and methods of designing and using same
UA118536C2 (uk) 2008-07-23 2019-02-11 Амбркс, Інк. Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування
US20110318322A1 (en) 2009-01-12 2011-12-29 Nektar Therapeutics Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer
US20120148604A1 (en) 2009-08-20 2012-06-14 Transposagen Biopharmaceuticals, Inc. Trp inhibitors and uses thereof
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN102753573A (zh) 2009-12-21 2012-10-24 Ambrx公司 经过修饰的牛促生长素多肽和其用途
NZ600363A (en) 2009-12-21 2014-07-25 Ambrx Inc Modified porcine somatotropin polypeptides and their uses
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
BR112013003522B1 (pt) 2010-08-17 2021-05-25 Ambrx, Inc. polipeptídeos relaxina modificados compreendendo um aminoácido não codificado naturalmente, seu método de preparação e seu uso, bem como ácido nucleico e célula hospedeira
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
HUE041294T2 (hu) 2011-12-16 2019-05-28 Poseida Therapeutics Inc TRPC4 modulátorok a fájdalom kezelésére vagy megelõzésére
US20130252280A1 (en) * 2012-03-07 2013-09-26 Genformatic, Llc Method and apparatus for identification of biomolecules
WO2014144963A1 (en) * 2013-03-15 2014-09-18 Alexandre Zanghellini Automated method of computational enzyme identification and design
WO2014201566A1 (en) * 2013-06-21 2014-12-24 Zymeworks Inc. Systems and methods for physical parameter fitting on the basis of manual review
US10381326B2 (en) 2014-05-28 2019-08-13 Invensas Corporation Structure and method for integrated circuits packaging with increased density
US10988514B2 (en) 2016-04-01 2021-04-27 University Of Washington Polypeptdes capable of forming homo-oligomers with modular hydrogen bond network-mediated specificity and their design
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
US20190325986A1 (en) * 2018-04-24 2019-10-24 Samsung Electronics Co., Ltd. Method and device for predicting amino acid substitutions at site of interest to generate enzyme variant optimized for biochemical reaction
US20220056093A1 (en) 2018-09-11 2022-02-24 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
EP3867265A1 (de) 2018-10-19 2021-08-25 Ambrx, Inc. Interleukin-10 -polypeptid-konjugate, dimere davon und ihre verwendungen
KR20220151202A (ko) 2020-03-11 2022-11-14 암브룩스, 인코포레이티드 인터류킨-2 폴리펩타이드 접합체 및 그의 사용 방법
CN114495243B (zh) * 2022-04-06 2022-07-05 第六镜科技(成都)有限公司 图像识别模型训练及图像识别方法、装置、电子设备

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939666A (en) * 1987-09-02 1990-07-03 Genex Corporation Incremental macromolecule construction methods
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5265030A (en) * 1990-04-24 1993-11-23 Scripps Clinic And Research Foundation System and method for determining three-dimensional structures of proteins
US5241470A (en) * 1992-01-21 1993-08-31 The Board Of Trustees Of The Leland Stanford University Prediction of protein side-chain conformation by packing optimization
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5878373A (en) * 1996-12-06 1999-03-02 Regents Of The University Of California System and method for determining three-dimensional structure of protein sequences
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
DE69810603T2 (de) * 1997-04-11 2003-11-13 California Inst Of Techn Gerät und verfahren für automatischen protein-entwurf
US20020048772A1 (en) * 2000-02-10 2002-04-25 Dahiyat Bassil I. Protein design automation for protein libraries
US6403312B1 (en) * 1998-10-16 2002-06-11 Xencor Protein design automatic for protein libraries
AU774334B2 (en) 1998-10-16 2004-06-24 Xencor Protein design automation for protein libraries
US20030049654A1 (en) * 1998-10-16 2003-03-13 Xencor Protein design automation for protein libraries
US7315786B2 (en) * 1998-10-16 2008-01-01 Xencor Protein design automation for protein libraries
WO2000068396A2 (en) 1999-05-12 2000-11-16 Xencor, Inc. Bacillus circulans xylanase mutants
DE60113381T2 (de) 2000-02-10 2006-06-29 Xencor, Monrovia Automatisierung im proteinentwurf durch proteinbibliotheken
US20030130827A1 (en) * 2001-08-10 2003-07-10 Joerg Bentzien Protein design automation for protein libraries

Also Published As

Publication number Publication date
US6708120B1 (en) 2004-03-16
US20060019316A1 (en) 2006-01-26
US6804611B2 (en) 2004-10-12
EP0974111B1 (de) 2003-01-08
US20050038610A1 (en) 2005-02-17
AU751331B2 (en) 2002-08-15
EP0974111A1 (de) 2000-01-26
JP2002510966A (ja) 2002-04-09
DK0974111T3 (da) 2003-04-22
US20010032052A1 (en) 2001-10-18
US6269312B1 (en) 2001-07-31
US20010039480A1 (en) 2001-11-08
US20020004706A1 (en) 2002-01-10
US6950754B2 (en) 2005-09-27
WO1998047089A1 (en) 1998-10-22
AU6965498A (en) 1998-11-11
CA2286262A1 (en) 1998-10-22
US20020106694A1 (en) 2002-08-08
US6792356B2 (en) 2004-09-14
US6801861B2 (en) 2004-10-05
US6188965B1 (en) 2001-02-13
US20060259247A1 (en) 2006-11-16
US20070032961A1 (en) 2007-02-08
DE69810603D1 (de) 2003-02-13

Similar Documents

Publication Publication Date Title
DE69810603D1 (de) Gerät und verfahren für automatischen protein-entwurf
DE69837578D1 (de) Verfahren und Gerät für automatische Sprachmodusselektion
DE69723439D1 (de) Display und verfahren für digitaloszilloskop
DE1028661T1 (de) Mittel und verfahren für percutane myokordiale revaskuöarisationswachstumsfaktoren
DE69736764D1 (de) Lokales Positionierungsgerät und Verfahren dafür
DE69834401D1 (de) Businterfacesystem und verfahren
DE69816789D1 (de) Verfahren und system zur gestengesteuerten optionsauswahl
DE69621608T2 (de) Vorrichtung und verfahren für kapillarelektrophorese
DE69804759D1 (de) Verfahren und gerät für zeitbereichsreflektometrie (otdr)
DE69804708T2 (de) Verfahren und Gerät für Grössenoptimierung von Speichereinheiten
DE69736760D1 (de) Gerät und Verfahren für Telekommunikationsleitweglenkung
DE69831519D1 (de) System und Verfahren zur Lageermittlung
DE59805235D1 (de) Testsystem und testverfahren
DE69739776D1 (de) Verfahren zum Empfangen und Empfänger für OFDM-Signale
DE69830843D1 (de) Vorrichtung und verfahren für überkritische reaktion
DE69700087D1 (de) Gerät und Verfahren zur Signalanalyse
DE69738664D1 (de) Elektrostatographisches Druckgerät und Verfahren
DE69736743D1 (de) Verfahren und einrichtung für richtfunkkommunikation
DE59710226D1 (de) Einrichtung und verfahren zur leckageerkennung
DE59802238D1 (de) Verfahren und giesseinrichtung für feinguss
DE69934787D1 (de) Navigationsvorrichtung und verfahren
DE69816818D1 (de) Mehrheitsentscheidungsvorrichtung und entsprechendes verfahren
DE69821022D1 (de) Auswringverfahren und auswringeinrichtung für fussbodenwischgerät
DE69711825D1 (de) Läppvorrichtung und Verfahren
DE69808881T2 (de) Verfahren und einrichtung zum verbesserten verbindungsaufbau

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee